Boston Scientific appoints Dr. Cheryl Pegus to board; amends $2.75B credit facility

BOSTON SCIENTIFIC CORP

Dr. Cheryl Pegus elected to board as tenth director, effective May 8, 2024; will serve on compensation and risk committees.
Pegus brings 25+ years of clinical and business leadership; most recently partner at Morgan Health, formerly EVP at Walmart and CMO at Walgreens.
Company amended its $2.75B revolving credit agreement, extending maturity to May 2029 for consenting lenders and adjusting the pricing grid.
Reset EBITDA exclusion cap for restructuring charges to $500M since March 31, 2024 (previously December 31, 2022).

item 5.02 item 5.03 item 7.01 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Cheryl Pegus

Director

BSX · BOSTON SCIENTIFIC CORP

Effective: 2024-05-08
Filed: May 10, 2024, 7:59 PM ET

appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Cheryl Pegus was appointed as Director at BOSTON SCIENTIFIC CORP.

Action: appointed
Role: Director

Exact text from the filing

appointed Cheryl Pegus, MD, MPH, to be a director of the Company, to hold office until the next annual meeting of stockholders, effective May 8, 2024.

View on SEC.gov

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-24-000050

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.